Company: Telomir Pharmaceuticals, Inc.

Form Type: 8-K

Filing Date: 2025-05-21

Type: New

Accession Number: 000164117225011868

Filing Summary: On May 19, 2025, Telomir Pharmaceuticals, Inc. raised $3 million in a straight equity sale without warrants or discounts. This investment came from The Bayshore Trust, the company's largest shareholder, for 1 million restricted shares at $3.00 each, an 18% premium to the closing price of $2.54. This financing aims to support the upcoming IND submission for the Telomir-1 drug in a rare disease indication. The transaction follows an earlier $1 million investment and complements a $5 million line of credit from the same shareholder group. The company has claimed exemption from registration requirements under the Securities Act for this private placement.

Form Type: 8-K

Filing Date: 2025-05-21

Type: New

Accession Number: 000164117225011938

Filing Summary: On May 15, 2025, Telomir Pharmaceuticals, Inc. reported the resignation of Michelle Yanez as Chief Financial Officer, Treasurer, and Secretary, effective May 16, 2025. Her departure was mutually agreed upon and not due to disagreements with the Company. Concurrently, Alan Weichselbaum was appointed as the new Chief Financial Officer, effective May 15, 2025. Weichselbaum has over 30 years of experience in corporate finance and strategic advisory. An Employment Agreement was established under which Weichselbaum will receive a $60,000 salary and 50,000 options for purchasing the Company's stock, with specific vesting timelines contingent on his continued employment. The report includes an exhibit (10.1) that details the Employment Agreement.

Form Type: 8-K

Filing Date: 2025-05-15

Type: New

Accession Number: 000164117225010518

Filing Summary: On May 15, 2025, Telomir Pharmaceuticals, Inc. announced the identification of Telomir-Ag2 as a novel drug candidate following successful preclinical validation of its antimicrobial activity. Telomir-Ag2, a stabilized Silver(II) complex developed using the Company’s proprietary Telomir-1 platform, demonstrated broad-spectrum antibacterial activity against both Gram-positive and Gram-negative strains in a recent Minimum Inhibitory Concentration (MIC) study, including resistance strains such as methicillin- and aminoglycoside-resistant Staphylococcus aureus. This compound showed greater antibacterial activity compared to Telomir’s previous Silver(I)-based formulation, Telomir-Ag1. This development highlights the Company’s breakthrough in maintaining the stability of Silver(II) in a biologically compatible form, which is significant given Silver(II)'s high oxidative potential and antimicrobial properties. Telomir believes this advancement may aid in combating drug-resistant infections in critical environments like burn wounds and post-surgical complications. The Company intends to pursue formulation development and evaluate strategic and regulatory pathways for Telomir-Ag2.

Form Type: 10-Q

Filing Date: 2025-05-14

Type: New

Accession Number: 000164117225010298

Filing Summary: Telomir Pharmaceuticals, Inc. reported its quarterly results for the period ended March 31, 2025, in its Form 10-Q filing on May 14, 2025. The report shows a significant cash decrease, with current assets valued at $491,188, compared to $1,324,005 at the end of the previous year. The company reported no revenues and a net loss of $2,179,828 for the quarter, an improvement from a net loss of $6,254,607 in the same period last year. Operating costs increased, primarily due to general and administrative expenses and research and development costs. The company has a stockholders' deficit of $161,106 and faces substantial doubt about its ability to continue as a going concern without raising additional funds. As of the filing date, there were 29,762,671 shares of common stock outstanding. The company continues to seek capital funding for ongoing operations and future clinical trials involving its drug candidate, Telomir-1, which targets various health conditions, including age-related diseases and infections. The report emphasizes the need for external financing and outlines a related party licensing agreement for its primary product, Telomir-1, with no upfront payment obligations, but with an 8% royalty structure in place.

Form Type: 8-K

Filing Date: 2025-05-07

Type: New

Accession Number: 000164117225008956

Filing Summary: Telomir Pharmaceuticals, Inc. has announced new preclinical data demonstrating that its lead oral drug candidate, Telomir-1, reverses key drivers of cellular decline in human cell lines. The study, conducted with SmartAssays, shows improvements in mitochondrial activity, reduction of oxidative stress, restoration of calcium balance, and protection from toxic metal effects. These findings support the company's new research initiatives in treating autism spectrum disorder and spasmodic dysphonia. Improved cell viability under stress, boosted mitochondrial function, decreased reactive oxygen species (ROS), restored calcium signaling, and protection against metal-induced toxicity were key results of the study, suggesting Telomir-1's potential in addressing cellular stress mechanisms linked to aging and chronic diseases.

Form Type: 8-K

Filing Date: 2025-03-19

Type: New

Accession Number: 000149315225010868

Filing Summary: Telomir Pharmaceuticals, Inc. published significant preclinical findings regarding its drug Telomir-1, which exhibits notable anti-cancer effects in an animal model of prostate cancer. The data shows that Telomir-1 can reduce tumor size by approximately 50% when tested on aggressive human prostate cancer cells. Additionally, the drug actively suppresses cancer growth and offers protection against the toxic effects associated with chemotherapy, particularly when paired with Paclitaxel, a common chemotherapy agent known for its toxicity. The findings highlight that while treatment with Paclitaxel alone resulted in severe toxicity and mortality among the test subjects, the incorporation of Telomir-1 at low doses resulted in no reported fatalities. These outcomes suggest that Telomir-1 offers promising therapeutic benefits by protecting healthy cells while inhibiting cancer progression.

Form Type: CORRESP

Filing Date: 2025-02-26

Type: New

Accession Number: 000149315225008285

Filing Summary: Telomir Pharmaceuticals, Inc. has requested the acceleration of the effective date for its Registration Statement on Form S-3, File No. 333-284990. The company seeks for the Registration Statement to become effective at 9:00 a.m. Eastern Time on February 28, 2025, or as soon thereafter as possible, in accordance with Rule 461 of the Securities Act of 1933. This request was submitted to the U.S. Securities & Exchange Commission's Division of Corporation Finance Office of Life Sciences.

Form Type: 8-K

Filing Date: 2025-02-25

Type: New

Accession Number: 000149315225008195

Filing Summary: Telomir Pharmaceuticals, Inc. announced new preclinical findings regarding its drug, Telomir-1, which effectively reverses calcium dysregulation, a significant factor in both cellular aging and disease progression, across various human cell lines. The study focused on human keratinocyte (HaCaT) and retinal (ARPE-19) cells, revealing that Telomir-1 is capable of reducing intracellular calcium overload, alleviating oxidative stress, and enhancing cellular integrity under stress conditions. Untreated cells displayed degeneration and death, while treated cells showed improved resilience and stability. Telomir-1 is positioned to preserve cellular functions and prevent cell death pathways, indicating potential in addressing aging-related health issues. The company is advancing its preclinical studies towards human trials as a promising therapy for neurodegenerative disorders, retinal diseases, and metabolic dysfunction.

Form Type: 8-K

Filing Date: 2025-02-20

Type: New

Accession Number: 000149315225007698

Filing Summary: Telomir Pharmaceuticals, Inc. announced a significant breakthrough in silver ion stabilization with its product Telomir-1. This innovation successfully captures and stabilizes Silver(I) and the reactive Silver(II) in a biologically compatible form, overcoming major limitations for silver's medical applications. The stabilization of Silver(II) offers superior antimicrobial properties and can potentially accelerate tissue repair, making it crucial for advanced antimicrobial treatments, wound care, and infection-resistant coatings. The findings suggest new commercial opportunities in the medical and biotech sectors. Telomir plans to continue preclinical research and explore regulatory pathways for its Silver(II)-complexed Telomir-1, positioning itself to lead the development of next-generation topical wound care therapies.

Form Type: S-3

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006943

Filing Summary: Telomir Pharmaceuticals, Inc. filed a registration statement with the SEC on February 14, 2025, under Form S-3. This registration allows the company to offer securities with a total aggregate initial offering price of up to $150,000,000, which may include common stock, preferred stock, warrants, and/or units. The company has plans to issue up to $100,000,000 of common stock under an At The Market Offering Agreement with Rodman & Renshaw LLC. The filing includes a base prospectus and will be supplemented with specific terms when securities are being offered. As a smaller reporting and emerging growth company, Telomir Pharmaceuticals benefits from reduced disclosure requirements. The document discusses the therapeutic potential of Telomir-1, a drug aimed at combating oxidative stress and related diseases by moderating essential metal ions, and includes details on risk factors and investment strategies related to their offerings. The company's common stock is listed on the Nasdaq under the symbol “TELO”.

Form Type: 10-K

Filing Date: 2025-02-04

Type: New

Accession Number: 000149315225004872

Filing Summary: Telomir Pharmaceuticals, Inc. filed its annual report on Form 10-K for the fiscal year ending December 31, 2024. The company focuses on Telomir-1, an innovative oral small molecule that aims to regulate metal ions to combat oxidative stress, a significant factor in aging and various diseases. Telomir-1 is designed to extend telomeres and protect against conditions like Progeria, Wilson’s disease, Type 2 Diabetes, Alzheimer's disease, and certain cancers. The report details preclinical studies indicating Telomir-1’s efficacy in mitigating oxidative damage and potentially reversing cellular aging. The company collaborates with various research organizations to test Telomir-1’s therapeutic potential, with ongoing studies to investigate its effects on conditions like diabetes and age-related diseases. Additionally, the report confirms Telomir Pharmaceuticals is not a shell company and has filed all necessary reports as required by the SEC.

Form Type: 8-K

Filing Date: 2025-01-07

Type: New

Accession Number: 000149315225001112

Filing Summary: Telomir Pharmaceuticals, Inc. announced significant findings from a preclinical study on progeria, confirming that their compound Telomir-1 can restore the lifespan of nematodes with a genetic mutation related to Werner Syndrome, which models rapid aging. This suggests Telomir-1 may address cellular issues causing rapid aging and associated health problems. The report includes a cautionary note regarding forward-looking statements, noting that actual future results may differ from predictions based on the study's relevance to the company's development and testing plans.

Form Type: 8-K

Filing Date: 2024-12-23

Type: New

Accession Number: 000149315224051191

Filing Summary: On December 23, 2024, Telomir Pharmaceuticals, Inc. announced important findings from preclinical studies regarding its lead compound, Telomir-1, highlighting its strong copper-binding capabilities. This finding positions Telomir-1 as a potential treatment for Wilson’s disease, which is characterized by excessive copper accumulation, and related copper disorders. The compound's ability to selectively regulate copper metabolism and its interaction with essential ions suggests it may overcome existing treatment limitations. The company plans to advance preclinical studies specifically in Wilson’s disease and is exploring additional indications. A submission for an Investigational New Drug (IND) and Investigational New Animal Drug (INAD) application is anticipated by Q4 2025, with clinical trials slated to begin in 2026. Additionally, the report contains forward-looking statements regarding the expected impact of these study results on the company’s future development and testing of Telomir-1, but cautions that actual outcomes may differ significantly from the predictions made.